Indian Patents. 262726:BIPHENYL IMIDAZOLE COMPOUNDS

Title of Invention	BIPHENYL IMIDAZOLE COMPOUNDS
Abstract	Biphenyl compounds of Formula I: are novel compounds, their pharmaceuticall y acceptable salts or solvates and their pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicines to treat inflammation and process for preparing the same, and novel use of the compounds of Formula II to treat inflammation in any living bodies.

Full Text	FORM 2 THE PATENT ACT 1970 (39 of 1970) & The Patents Rules, 2003 PROVISIONAL SPECIFICATION (See section 10 and rule 13) 1. TITLE OF THE INVENTION Anti inflammatory compounds. 2. APPLICANT (S) (a) NAME : ELDER PHARMACEUTICALS LTD. (b) NATIONALITY : INDIAN (c) ADDRESS : Elder House, Plot No. C/9, Dalia Indl. Estate, Off. New Link Road, Andheri (W), Mumbai-400 058,. India 3. PREAMBLE TO THE DESCRIPTION The following specification describes the invention. 1856 2 SEP 2008 4. DESCRIPTION: FIELD OF THE INVENTION: The present invention relates to the novel compounds and known compounds and its pharmaceutically acceptable salts, and its solvates, to a process for preparing such compounds, to pharmaceutical compositions containing compounds and to the use of such compounds and composition in reducing the inflammation in living bodies. This invention particularly relates to novel compounds of the general Formula I: Formula I: and its pharmaceutically acceptable salts, and its solvates, to a process for preparing such compounds, to pharmaceutical compositions containing compounds and to the use of such compounds and composition in medicines. The invention also relates to use compounds of Formula II for treating inflammation in living bodies. 2 Formula II BACKGROUND OF THE INVENTION: Inflammation is a complex stereotypical reaction of the body expressing the response to damage of its cells and vascularized tissues. The inflammatory process is designed to provide a rapid mechanism by which the host can respond to the invasion of foreign material and return to homeostatic equilibrium. The biosynthetic cascade of arachidonic acid has been the object of intense research. Arachidonic acid is present in cell membranes as esters of phosphorylated glycerides, the so-called phospho¬lipids. Under some defined biological stimulus, certain lipases can hydrolyze, either directly or in stepwise fashion, these phosphorylated arachidonic glycerides to release free arachidonic acid. The lipases that perform such function, most prominent is the enzyme Phopholipase A2; this enzyme hydrolyzes the phospholipids and releases arachidonic acid in a single step. Arachidonic acid liberated from phospholipids by various stimulants, can be metabolized by a group of enzymes such as (a) arachidonoyl-CoA synthetase and arachidonoyl -CoA:lyophospholipid transferase reincorporate arachidonic acid back onto phospholipids, (b) the cyciooxygenase (COX) which are further sub divided mainly into cyclooxygehase-1 (COX-1) and cyclooxygenase-2 (COX-2) pathway to pro-inflammatory prostaglandins (PGs) and thromboxane A2 (c) lipoxygenase (LOX) pathways to hydroperoxy eicosatetraenoic acids (HPETEs), hydroxy eicosatetraenoic acids (HETEs) and leukotrienes (LTs). Lipoxygenases exist in three lipoxygenases (5-lipoxygenase, 12-lipoxygenase, 15-lipoxygenase), and the most prominent is 5-lipoxygenase. 5-Lipoxygenase metabolises 3 arachidonic acid into leukotrienes. Zileuton is an example of 5-iipoxygenase inhibitor, belonging to the N-hydroxyurea class of compounds. 5-Lipoxygenase operates in a much more complex way. For 5-lipoxygenase to be effective, it needs the cofaclors Ca2+, ATP and another protein nicknamed 5-FLAP (5-Lipoxygenase activating protein), a membrane protein. 5-Lipoxygenase relocates to the membrane binding with the three cofactors mentioned and starts the transformation of arachidonic acid eventually to result in leukotrienes. Inhibitors of the 5-FLAP are effective anti-inflammatory compounds switching off the 5-lipoxygenase chain. Among the 5-FLAP inhibitors may be mentioned, MK-866, (±) 2-fluoro-a-methyl-1,l'-biphenyl]-4-acetic acid. (Novel Inhibitors of Leukotriene, Edited by G. Folco, B, Samuelson, R. C. Murphy, Birkhlauser Verlag, Basel, 1999), (d) cytochrome P450 pathways to an epoxide, epoxyeicosatrienoic acid which further is converted to diols through the agency of epoxide hydrolases, (e) diffusion of arachidonic acid outside the cell. Finally arachidonic acid can also be transformed into its ethanol amide, called Anadamide, identified as an endogenous ligand for cannabinoid receptors in brain cells. Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) namely, indomethacin, flurbiprofen, ketoprofen, ketorolac, diclofenac and tolfenamic acid are used as first line therapy for relieving pain and inflammation. Chronic use of these drugs has been associated with the propensity for side effects such as gastrointestinal irritation (mucosal damage, bleeding) and also at the renal level, thereby limiting their therapeutic potential. In order to overcome these side effects, worldwide research activities focused on developing safer NSAIDs- as selective COX-2 inhibitors. Several selective COX-2 inhibiting drugs such as Celecoxib (J. Med.Chem. 1997, 40(9), 1347-1365), Rofecoxib (Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778), Valdecoxib (J. Med Chem. 2000, 43(5), 775-777), Parecoxib Na (J. Med Chem. 2000, 43(9), 1661-1663) and etoricoxib (J. Pharmacol. Exp. Ther. 2002,296(2), 558-566) are being marketed as a new generation of NSAIDs. Some of these NSAIDs are represented in (Fig:A) 4 CH3OH Ketoprofen Indomethacin Flurbiprofen H CH3 .N 3 COOH COOH Diclofenac Tolfenamic acid H3C O O O H3C. O O' Rofecoxib Celecoxib Etoricoxib Fig A. Chemical structures of NSAIDs and selective COX-2 inhibitors. However, some of selective COX-2 inhibitors were found having similar side effects on edema, hypertension as of conventional NSAIDs and the potentially increased risk of thrombosis associated with these inhibitors (N. Eng. J. Med 2000, 343:1520-1528). While gastrointestinal safety of NSAIDs is a major limitation to the use of this class of drugs, there is an increased concern about their cardiovascular adverse effects. All such and other drawbacks associated with some of existing COX-2 drugs resulted in the withdrawal of 5 rofecoxib (Vioxx; Merck & Co, Inc, Whitehouse Station, NJ) in particular, from worldwide markets. Thus it is an issue of the importance of targeting selectivity for COX-2 and/or COX-1 (Circulation 2004, 109, 2068-2073). Although several NSAIDs are in clinical practice even now, their use has been limited due to unwanted side effects. Discovery of an effective NSAID, which would be free from gastrointestinal irritation, ulcerogenicity, etc. make the research work a challenging task which ultimately is the aim of new drug development. The present investigation is aimed for the development of novel and NSAID useful for the treatment of various types of pain and inflammatory disorder. These molecules were designed on the basis of 3-D-Quantitative structure-activity relationship (QSAR) and molecular modeling studies performed on a known NSAIDs (J. Chem. Inf. Model., 2007, 47 (2), 635 -643). The results encouraged inventors to synthesis and screened for anti inflammatory activity against Carrageenan-induced rat paw edema model. OBJECTIVE OF THE INVENTION The main object of the present invention relates to the development of novel biphenyl imidazole compounds and use of these compounds to treat inflammatory disorders. Novel use of compounds of Formula II to treat any inflammation in the living bodies. Object of the present invention is to overcome the side effects of the existing NSAIDs. such as gastrointestinal irritation, ulcerogenicity. with improved anti inflammatory effect. 6 SUMMARY OF THE INVENTION: The compounds of Formula I: Formula I Where in, Imidazole ring is substituted with one or more of Rl group, Where in, Rl is H, -NO2, R4, -O-R4, -NH2, -SO2NH2, -NHSO2-R4, halo, -COOH, -CHO, -CN; R2 is H, -O-(CH2)n-R4 where in n = 0 to 5, - NO2, -SO2NH2, -NHSO2-R4, -CN, -COOH, halo, optionally substituted amino group, R4, cyclo alkyl group, alkyl thio, acyl group, substituted or unsubstituted heterocyclic group, alkoxy carbonyl, aryloxy, aryloxy carbonyl, substituted or unsubstituted amide; R3 is H: R4 is any substituted or unsubstituted alkyl; are novel compounds and their pharmaceutically acceptable salts or solvates. Pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicines to treat inflammation and process for preparing the same and novel use of compounds of Formula II: 7 Formula II where in, R5 is one or more of H, halo, NO2, R4, alkoxy carbonyl, -0-(CH2)n-R4 where in n is 0 to 5, COOH, -SO2NH2, -NHSO2-R4, aryl, cycloalkyJ, benzyl or substituted benzyl optionally substituted on phenyl ring with atleast one halogen, CN, -(CH2)m-R7 where in m is 0 to 5, - (CH2)p-OC(O)R4 where in p isl to 5, substituted or unsubstituted amine; R6 is one or more of CN, H, halo, NO2, R4, alkoxy carbonyl. -0-(CH2)n-R4 where in n is 0 to 5, -COOH, -SO2NH2, -NHSO2-R4, SO2-NH-R4, aryl, substituted or unsubstituted heterocyclic group, -CH2COOH, -CH2COOR4, -SO3H, -PO3H, substituted or unsubstituted amide, -CH2-R7, -CONH-R7 where in R7 is any substituted or unsubstituted heterocyclic group; R4 is any substituted or unsubstituted alky]. Compounds of this invention are significantly superior to compounds of known NSAID. 5. CLAIMS We claim, 1. Novel compounds of the Formula: I R1 .N. in which, Imidazole ring is substituted with one or more of Rl group, Where in, Rl is H, - NO2, R4, - O-R4, -NH2, -SO2NH2, -NHSO2-R4, halo, -COOH, -CHO, -CN; R2 is H, - O-(CH2)n-R4 where in n = 0 to 5, -NO2, -SO2NH2, -NHSO2-R4, -CN, -COOH, halo, optionally substituted amino group, R4, cyclo alkyl group, alkyl thio, acyl group, substituted or unsubstituted heterocyclic group, alkoxy carbonyl, aryloxy, aryloxy carbonyl, substituted or unsubstituted amide; R3 is H; R4 is any substituted or unsubstituted alkyl. 2. Use of compounds of Formula II to treat inflammation in living bodies. 9 6. SIGNATURE and DATE R5 is one or more of H, halo, NO2, R4, alkoxy carbonyl, - 0-(CH2)n-R4 where in n is 0 to 5, -COOH, - SO2NH2) -NHS02-R4, aryl, cycloalkyl, benzyl or substituted benzyl optionally substituted on phenyl ring with atleast one halogen, CN, -(CH2)m-R7 where in m is 0 to 5, -(CH2)p-OC(0)R4 where in p isl to 5, substituted or unsubstituted amine; R6 is one or more of CN, H, halo, NO2, R4, alkoxy carbonyl, -0-(CH2)n-R4 where in n is 0 to 5, -COOH, -SO2NH2, -NHSO2-R4, SO2-NH-R4, aryl, substituted or unsubstituted heterocyclic group, -CH2COOH, -CH2COOR4, -S03H, -P03H, substituted or unsubstituted amide, -CH2-R7 where in R7 is any substituted or unsubstituted heterocyclic group, -CONH-R7; R4 is any substituted or unsubstituted alkyl. 10

Full Text

FORM 2
THE PATENT ACT 1970
(39 of 1970)
&
The Patents Rules, 2003
PROVISIONAL SPECIFICATION
(See section 10 and rule 13)
1. TITLE OF THE INVENTION
Anti inflammatory compounds.
2. APPLICANT (S)
(a) NAME : ELDER PHARMACEUTICALS LTD.
(b) NATIONALITY : INDIAN
(c) ADDRESS : Elder House, Plot No. C/9, Dalia Indl. Estate,
Off. New Link Road, Andheri (W),
Mumbai-400 058,. India
3. PREAMBLE TO THE DESCRIPTION
The following specification describes the invention.

1856
2 SEP 2008

4. DESCRIPTION:
FIELD OF THE INVENTION: The present invention relates to the novel compounds and known compounds and its pharmaceutically acceptable salts, and its solvates, to a process for preparing such compounds, to pharmaceutical compositions containing compounds and to the use of such compounds and composition in reducing the inflammation in living bodies.
This invention particularly relates to novel compounds of the general Formula I:

Formula I:
and its pharmaceutically acceptable salts, and its solvates, to a process for preparing such
compounds, to pharmaceutical compositions containing compounds and to the use of such
compounds and composition in medicines.
The invention also relates to use compounds of Formula II for treating inflammation in living
bodies.
2

Formula II
BACKGROUND OF THE INVENTION: Inflammation is a complex stereotypical reaction of the body expressing the response to damage of its cells and vascularized tissues. The inflammatory process is designed to provide a rapid mechanism by which the host can respond to the invasion of foreign material and return to homeostatic equilibrium. The biosynthetic cascade of arachidonic acid has been the object of intense research. Arachidonic acid is present in cell membranes as esters of phosphorylated glycerides, the so-called phospho¬lipids. Under some defined biological stimulus, certain lipases can hydrolyze, either directly or in stepwise fashion, these phosphorylated arachidonic glycerides to release free arachidonic acid. The lipases that perform such function, most prominent is the enzyme Phopholipase A2; this enzyme hydrolyzes the phospholipids and releases arachidonic acid in a single step. Arachidonic acid liberated from phospholipids by various stimulants, can be metabolized by a group of enzymes such as (a) arachidonoyl-CoA synthetase and arachidonoyl -CoA:lyophospholipid transferase reincorporate arachidonic acid back onto phospholipids, (b) the cyciooxygenase (COX) which are further sub divided mainly into cyclooxygehase-1 (COX-1) and cyclooxygenase-2 (COX-2) pathway to pro-inflammatory prostaglandins (PGs) and thromboxane A2 (c) lipoxygenase (LOX) pathways to hydroperoxy eicosatetraenoic acids (HPETEs), hydroxy eicosatetraenoic acids (HETEs) and leukotrienes (LTs). Lipoxygenases exist in three lipoxygenases (5-lipoxygenase, 12-lipoxygenase, 15-lipoxygenase), and the most prominent is 5-lipoxygenase. 5-Lipoxygenase metabolises
3

arachidonic acid into leukotrienes. Zileuton is an example of 5-iipoxygenase inhibitor, belonging to the N-hydroxyurea class of compounds. 5-Lipoxygenase operates in a much more complex way. For 5-lipoxygenase to be effective, it needs the cofaclors Ca2+, ATP and another protein nicknamed 5-FLAP (5-Lipoxygenase activating protein), a membrane protein. 5-Lipoxygenase relocates to the membrane binding with the three cofactors mentioned and starts the transformation of arachidonic acid eventually to result in leukotrienes. Inhibitors of the 5-FLAP are effective anti-inflammatory compounds switching off the 5-lipoxygenase chain. Among the 5-FLAP inhibitors may be mentioned, MK-866, (±) 2-fluoro-a-methyl-1,l'-biphenyl]-4-acetic acid. (Novel Inhibitors of Leukotriene, Edited by G. Folco, B, Samuelson, R. C. Murphy, Birkhlauser Verlag, Basel, 1999), (d) cytochrome P450 pathways to an epoxide, epoxyeicosatrienoic acid which further is converted to diols through the agency of epoxide hydrolases, (e) diffusion of arachidonic acid outside the cell.
Finally arachidonic acid can also be transformed into its ethanol amide, called Anadamide, identified as an endogenous ligand for cannabinoid receptors in brain cells. Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) namely, indomethacin, flurbiprofen, ketoprofen, ketorolac, diclofenac and tolfenamic acid are used as first line therapy for relieving pain and inflammation. Chronic use of these drugs has been associated with the propensity for side effects such as gastrointestinal irritation (mucosal damage, bleeding) and also at the renal level, thereby limiting their therapeutic potential. In order to overcome these side effects, worldwide research activities focused on developing safer NSAIDs- as selective COX-2 inhibitors. Several selective COX-2 inhibiting drugs such as Celecoxib (J. Med.Chem. 1997, 40(9), 1347-1365), Rofecoxib (Bioorg. Med. Chem. Lett. 1999, 9, 1773-1778), Valdecoxib (J. Med Chem. 2000, 43(5), 775-777), Parecoxib Na (J. Med Chem. 2000, 43(9), 1661-1663) and etoricoxib (J. Pharmacol. Exp. Ther. 2002,296(2), 558-566) are being marketed as a new generation of NSAIDs. Some of these NSAIDs are represented in (Fig:A)
4

CH3OH

Ketoprofen

Indomethacin

Flurbiprofen

H CH3
.N 3

COOH

COOH

Diclofenac

Tolfenamic acid

H3C O

O O

H3C. O
O'

Rofecoxib

Celecoxib

Etoricoxib

Fig A. Chemical structures of NSAIDs and selective COX-2 inhibitors.
However, some of selective COX-2 inhibitors were found having similar side effects on edema, hypertension as of conventional NSAIDs and the potentially increased risk of thrombosis associated with these inhibitors (N. Eng. J. Med 2000, 343:1520-1528). While gastrointestinal safety of NSAIDs is a major limitation to the use of this class of drugs, there is an increased concern about their cardiovascular adverse effects. All such and other drawbacks associated with some of existing COX-2 drugs resulted in the withdrawal of
5

rofecoxib (Vioxx; Merck & Co, Inc, Whitehouse Station, NJ) in particular, from worldwide markets. Thus it is an issue of the importance of targeting selectivity for COX-2 and/or COX-1 (Circulation 2004, 109, 2068-2073).
Although several NSAIDs are in clinical practice even now, their use has been limited due to unwanted side effects. Discovery of an effective NSAID, which would be free from gastrointestinal irritation, ulcerogenicity, etc. make the research work a challenging task which ultimately is the aim of new drug development. The present investigation is aimed for the development of novel and NSAID useful for the treatment of various types of pain and inflammatory disorder.
These molecules were designed on the basis of 3-D-Quantitative structure-activity relationship (QSAR) and molecular modeling studies performed on a known NSAIDs (J. Chem. Inf. Model., 2007, 47 (2), 635 -643). The results encouraged inventors to synthesis and screened for anti inflammatory activity against Carrageenan-induced rat paw edema model.
OBJECTIVE OF THE INVENTION
The main object of the present invention relates to the development of novel biphenyl imidazole compounds and use of these compounds to treat inflammatory disorders. Novel use of compounds of Formula II to treat any inflammation in the living bodies. Object of the present invention is to overcome the side effects of the existing NSAIDs. such as gastrointestinal irritation, ulcerogenicity. with improved anti inflammatory effect.
6

SUMMARY OF THE INVENTION:
The compounds of Formula I:

Formula I Where in,
Imidazole ring is substituted with one or more of Rl group, Where in,
Rl is H, -NO2, R4, -O-R4, -NH2, -SO2NH2, -NHSO2-R4, halo, -COOH, -CHO, -CN; R2 is H, -O-(CH2)n-R4 where in n = 0 to 5, - NO2, -SO2NH2, -NHSO2-R4, -CN, -COOH, halo, optionally substituted amino group, R4, cyclo alkyl group, alkyl thio, acyl group, substituted or unsubstituted heterocyclic group, alkoxy carbonyl, aryloxy, aryloxy carbonyl, substituted or unsubstituted amide; R3 is H:
R4 is any substituted or unsubstituted alkyl;
are novel compounds and their pharmaceutically acceptable salts or solvates. Pharmaceutical compositions containing such compounds and the use of such compounds and compositions in medicines to treat inflammation and process for preparing the same and novel use of compounds of Formula II:
7

Formula II where in,
R5 is one or more of H, halo, NO2, R4, alkoxy carbonyl, -0-(CH2)n-R4 where in n is 0 to 5,
COOH, -SO2NH2, -NHSO2-R4, aryl, cycloalkyJ, benzyl or substituted benzyl optionally
substituted on phenyl ring with atleast one halogen, CN, -(CH2)m-R7 where in m is 0 to 5, -
(CH2)p-OC(O)R4 where in p isl to 5, substituted or unsubstituted amine;
R6 is one or more of CN, H, halo, NO2, R4, alkoxy carbonyl. -0-(CH2)n-R4 where in n is 0
to 5, -COOH, -SO2NH2, -NHSO2-R4, SO2-NH-R4, aryl, substituted or unsubstituted
heterocyclic group, -CH2COOH, -CH2COOR4, -SO3H, -PO3H, substituted or unsubstituted
amide, -CH2-R7, -CONH-R7 where in R7 is any substituted or unsubstituted heterocyclic
group;
R4 is any substituted or unsubstituted alky].
Compounds of this invention are significantly superior to compounds of known NSAID.

5. CLAIMS
We claim, 1. Novel compounds of the Formula: I
R1

.N.

in which,
Imidazole ring is substituted with one or more of Rl group, Where in,
Rl is H, - NO2, R4, - O-R4, -NH2, -SO2NH2, -NHSO2-R4, halo, -COOH, -CHO, -CN;
R2 is H, - O-(CH2)n-R4 where in n = 0 to 5, -NO2, -SO2NH2, -NHSO2-R4, -CN, -COOH, halo, optionally substituted amino group, R4, cyclo alkyl group, alkyl thio, acyl group, substituted or unsubstituted heterocyclic group, alkoxy carbonyl, aryloxy, aryloxy carbonyl, substituted or unsubstituted amide; R3 is H;
R4 is any substituted or unsubstituted alkyl. 2. Use of compounds of Formula II to treat inflammation in living bodies.
9

6. SIGNATURE and DATE
R5 is one or more of H, halo, NO2, R4, alkoxy carbonyl, - 0-(CH2)n-R4 where in n is 0 to 5, -COOH, - SO2NH2) -NHS02-R4, aryl, cycloalkyl, benzyl or substituted benzyl optionally substituted on phenyl ring with atleast one halogen, CN, -(CH2)m-R7 where in m is 0 to 5, -(CH2)p-OC(0)R4 where in p isl to 5, substituted or unsubstituted amine; R6 is one or more of CN, H, halo, NO2, R4, alkoxy carbonyl, -0-(CH2)n-R4 where in n is 0 to 5, -COOH, -SO2NH2, -NHSO2-R4, SO2-NH-R4, aryl, substituted or unsubstituted heterocyclic group, -CH2COOH, -CH2COOR4, -S03H, -P03H, substituted or unsubstituted amide, -CH2-R7 where in R7 is any substituted or unsubstituted heterocyclic group, -CONH-R7; R4 is any substituted or unsubstituted alkyl.
10

Documents:

1856-MUM-2008-ABSTRACT(PROVISIONAL)-(2-9-2008).pdf

1856-mum-2008-abstract.doc

1856-mum-2008-abstract.pdf

1856-MUM-2008-ABSTRCT(COMPLETE)-(18-8-2009).pdf

1856-MUM-2008-ANNEXURE I TO III(24-10-2011).pdf

1856-MUM-2008-ANNEXURE I(27-11-2012).pdf

1856-MUM-2008-ANNEXURE II(27-11-2012).pdf

1856-MUM-2008-ANNEXURE III(27-11-2012).pdf

1856-MUM-2008-CLAIMS(AMENDED)-(22-1-2013).pdf

1856-MUM-2008-CLAIMS(AMENDED)-(8-10-2013).pdf

1856-MUM-2008-CLAIMS(COMPLETE)-(18-8-2009).pdf

1856-MUM-2008-CLAIMS(MARKED COPY)-(22-1-2013).pdf

1856-MUM-2008-CLAIMS(MARKED COPY)-(8-10-2013).pdf

1856-MUM-2008-CLAIMS(PROVISIONAL)-(2-9-2008).pdf

1856-mum-2008-claims.doc

1856-mum-2008-claims.pdf

1856-MUM-2008-CORRESPONDENCE(18-8-2009).pdf

1856-MUM-2008-CORRESPONDENCE(23-3-2011).pdf

1856-MUM-2008-CORRESPONDENCE(24-10-2011).pdf

1856-MUM-2008-CORRESPONDENCE(27-11-2012).pdf

1856-MUM-2008-CORRESPONDENCE(7-4-2010).pdf

1856-MUM-2008-CORRESPONDENCE(8-12-2009).pdf

1856-mum-2008-correspondence.pdf

1856-MUM-2008-DESCRIPTION(COMPLETE)-(18-8-2009).pdf

1856-MUM-2008-DESCRIPTION(PROVISIONAL)-(2-9-2008).pdf

1856-mum-2008-form 1.pdf

1856-MUM-2008-FORM 18(8-12-2009).pdf

1856-MUM-2008-FORM 2(COMPLETE)-(18-8-2009).pdf

1856-MUM-2008-FORM 2(PROVISIONAL)-(2-9-2008).pdf

1856-MUM-2008-FORM 2(TITLE PAGE)-(COMPLETE)-(18-8-2009).pdf

1856-MUM-2008-FORM 2(TITLE PAGE)-(PROVISIONAL)-(2-9-2008).pdf

1856-mum-2008-form 2(title page).pdf

1856-mum-2008-form 2.doc

1856-mum-2008-form 2.pdf

1856-MUM-2008-FORM 3(2-9-2008).pdf

1856-MUM-2008-FORM 3(23-3-2011).pdf

1856-MUM-2008-FORM 3(24-10-2011).pdf

1856-MUM-2008-FORM 3(27-11-2012).pdf

1856-mum-2008-form 3.pdf

1856-MUM-2008-FORM 5(18-8-2009).pdf

1856-MUM-2008-REPLY TO EXAMINATION REPORT(22-1-2013).pdf

1856-MUM-2008-REPLY TO HEARING(8-10-2013).pdf

« Previous Patent

Next Patent »

Patent Number

262726

Indian Patent Application Number

1856/MUM/2008

PG Journal Number

37/2014

Publication Date

12-Sep-2014

Grant Date

09-Sep-2014

Date of Filing

02-Sep-2008

Name of Patentee

ELDER PHARMACEUTICALS LTD.

Applicant Address

ELDER HOUSE, PLOT NO C/9, DALIA INDL. ESTATE, OFF. NEW LINK ROAD, ANDHERI (WEST), MUMBAI.

Inventors:

#	Inventor's Name	Inventor's Address
1	SAKHARDANDE RAJIV RAWALNATH	8, DIPTI, HANUMAN CROSS ROAD NO. 1, VILEPARLE (EAST), MUMBAI-400 057.
2	KULKARNI VITHAL MADHVARAO	B-302, MONT VERT ALTESSE, SUS ROAD, PASHAN, PUNE-411 021.
3	WAGH NILESH KHANDU	OM GURUDEV, PLOT NO. 23, BHAUSAHEB HIRE SOCIETY, HIRAWADI, PANCHAVATI, NASIK-422 003.
4	NIMBALKAR MANMOHAN MADHAVRAO	46, UTKARSH SAYANI ROAD, KHED GALLI, PRABHADEVI, MUMBAI-400 025.

PCT International Classification Number

A61K31/216; A61K31/4184; A61K31/4245

PCT International Application Number

N/A

PCT International Filing date

PCT Conventions:

#	PCT Application Number	Date of Convention	Priority Country
1			NA